Incyte Corporation - Common Stock (NQ:INCY)

115.64 +2.33 (+2.06%)

Delayed Quote Updated: 12:04 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

29 30 Next >

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication ↗

August 15, 2024

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...

Via Benzinga

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

August 14, 2024

From Incyte and Syndax Pharmaceuticals

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

August 13, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 07, 2024

From Incyte

Via Business Wire

Analyst Ratings For Incyte ↗

July 26, 2024

Via Benzinga

Looking for growth without the hefty price tag? Consider NASDAQ:INCY. ↗

July 22, 2024

INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably.

Via Chartmill

After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial ↗

July 31, 2024

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference.

Via Benzinga

Topics Death

Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance ↗

July 30, 2024

Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi...

Via Benzinga

Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

July 30, 2024

From Incyte

Via Business Wire

NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

July 10, 2024

INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals.

Via Chartmill

S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday? ↗

July 09, 2024

The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s...

Via Benzinga

Topics Economy Stocks

NASDAQ:INCY is not too expensive for the growth it is showing. ↗

July 01, 2024

In the world of growth stocks, INCYTE CORP (NASDAQ:INCY) shines as a value proposition.

Via Chartmill

Incyte to Report Second Quarter Financial Results

July 09, 2024

From Incyte

Via Business Wire

The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024 ↗

July 09, 2024

The stock market watches this investing guru's picks closely but these may be the best undervalued Cathie Wood stocks in her ETFs.

Via InvestorPlace

7 Cheap Biotech Stocks With Major Upside Potential ↗

July 09, 2024

While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.

Via InvestorPlace

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 08, 2024

From Incyte

Via Business Wire

Analyst Expectations For Incyte's Future ↗

June 18, 2024

Via Benzinga

Despite its growth, NASDAQ:INCY remains within the realm of affordability. ↗

June 10, 2024

Don't overlook INCYTE CORP (NASDAQ:INCY)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

3 Highly Rated Biotech Stocks for Your July Buy List ↗

July 05, 2024

Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.

Via InvestorPlace

This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

July 02, 2024

Via Benzinga

Stocks Chop As Wall Street Unpacks Powell Comments ↗

July 02, 2024

Stocks are mixed at midday, as investors weigh remarks from Federal Reserve Chair Jerome Powell.

Via Talk Markets

Topics Economy

7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗

July 01, 2024

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.

Via InvestorPlace

For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. ↗

June 19, 2024

In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers ↗

June 13, 2024

The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing at 19,576 points and reaching all-time highs.

Via Benzinga

Topics Stocks

Incyte Announces Final Results of Tender Offer

June 13, 2024

From Incyte Corporation

Via Business Wire

Incyte Announces Preliminary Results of Tender Offer

June 11, 2024

From Incyte Corporation

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 07, 2024

From Incyte

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2024

Via Benzinga

Incyte Completes Acquisition of Escient Pharmaceuticals

May 30, 2024

From Incyte

Via Business Wire

When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

May 29, 2024

INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.